These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 21963050)
61. Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores? Makarov DV; Sanderson H; Partin AW; Epstein JI J Urol; 2002 Jun; 167(6):2440-2. PubMed ID: 11992053 [TBL] [Abstract][Full Text] [Related]
62. Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter. Ahyai SA; Graefen M; Steuber T; Haese A; Schlomm T; Walz J; Köllermann J; Briganti A; Zacharias M; Friedrich MG; Karakiewicz PI; Montorsi F; Huland H; Chun FK Eur Urol; 2008 Apr; 53(4):750-7. PubMed ID: 17964070 [TBL] [Abstract][Full Text] [Related]
63. Prevalence of prostate cancer at different levels of serum prostate-specific antigen (PSA) and different free: total PSA ratios in a consecutive series of men referred for prostate biopsies. Rydén L; Egevad L; Ekman P; Hellström M Scand J Urol Nephrol; 2007; 41(4):302-7. PubMed ID: 17763221 [TBL] [Abstract][Full Text] [Related]
64. Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience. Recker F; Kwiatkowski MK; Huber A; Stamm B; Lehmann K; Tscholl R J Urol; 2001 Sep; 166(3):851-5. PubMed ID: 11490232 [TBL] [Abstract][Full Text] [Related]
65. Obesity is associated with higher risk of prostate cancer detection in a biopsy population in Korea. Park J; Cho SY; Lee SB; Son H; Jeong H BJU Int; 2014 Dec; 114(6):891-5. PubMed ID: 24314095 [TBL] [Abstract][Full Text] [Related]
66. [The detection rate of prostate cancer in different prostate-specific antigen (PSA) levels in Chinese men]. Li M; Na YQ Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(1):16-8. PubMed ID: 18346372 [TBL] [Abstract][Full Text] [Related]
67. Obesity as a predictor of biochemical recurrence and survival after radiation therapy for prostate cancer. Palma D; Pickles T; Tyldesley S; BJU Int; 2007 Aug; 100(2):315-9. PubMed ID: 17617138 [TBL] [Abstract][Full Text] [Related]
68. Active surveillance for the management of prostate cancer in a contemporary cohort. Dall'Era MA; Konety BR; Cowan JE; Shinohara K; Stauf F; Cooperberg MR; Meng MV; Kane CJ; Perez N; Master VA; Carroll PR Cancer; 2008 Jun; 112(12):2664-70. PubMed ID: 18433013 [TBL] [Abstract][Full Text] [Related]
69. Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE. Kane CJ; Bassett WW; Sadetsky N; Silva S; Wallace K; Pasta DJ; Cooperberg MR; Chan JM; Carroll PR J Urol; 2005 Mar; 173(3):732-6. PubMed ID: 15711258 [TBL] [Abstract][Full Text] [Related]
70. The prevalence of erectile dysfunction among Brazilian men screened for prostate cancer. Paranhos M; Antunes A; Andrade E; Freire G; Srougi M BJU Int; 2009 Oct; 104(8):1130-3. PubMed ID: 19426190 [TBL] [Abstract][Full Text] [Related]
71. Influence of body mass index and total testosterone level on biochemical recurrence following radical prostatectomy. Hisasue S; Yanase M; Shindo T; Iwaki H; Fukuta F; Nishida S; Muranaka T; Miyamoto S; Tsukamoto T; Takatsuka K Jpn J Clin Oncol; 2008 Feb; 38(2):129-33. PubMed ID: 18281308 [TBL] [Abstract][Full Text] [Related]
72. Influence of anthropometric measurements, age, and prostate volume on prostate-specific antigen levels in men with a low risk of prostate cancer. Ochiai A; Fritsche HA; Babaian RJ Urology; 2005 Oct; 66(4):819-23. PubMed ID: 16230145 [TBL] [Abstract][Full Text] [Related]
73. The independent impact of extended pattern biopsy on prostate cancer stage migration. Master VA; Chi T; Simko JP; Weinberg V; Carroll PR J Urol; 2005 Nov; 174(5):1789-93; discussion 1793. PubMed ID: 16217288 [TBL] [Abstract][Full Text] [Related]
74. Absence of relationship between steroid hormone levels and prostate cancer tumor grade. Sher DJ; Mantzoros C; Jacobus S; Regan MM; Lee GS; Oh WK Urology; 2009 Feb; 73(2):356-61; discussion 361-2. PubMed ID: 19036418 [TBL] [Abstract][Full Text] [Related]
75. Circulating estradiol, but not testosterone, is a significant predictor of high-grade prostate cancer in patients undergoing radical prostatectomy. Salonia A; Gallina A; Briganti A; Suardi N; Capitanio U; Abdollah F; Bertini R; Freschi M; Rigatti P; Montorsi F Cancer; 2011 Nov; 117(22):5029-38. PubMed ID: 21495024 [TBL] [Abstract][Full Text] [Related]
76. Metabolic syndrome increases the risk of aggressive prostate cancer detection. Morote J; Ropero J; Planas J; Bastarós JM; Delgado G; Placer J; Celma A; de Torres IM; Carles J; Reventós J; Doll A BJU Int; 2013 Jun; 111(7):1031-6. PubMed ID: 22883053 [TBL] [Abstract][Full Text] [Related]
77. Does obesity affect the accuracy of prostate-specific antigen (PSA) for predicting prostate cancer among men undergoing prostate biopsy. Oh JJ; Jeong SJ; Lee BK; Jeong CW; Byun SS; Hong SK; Lee SE BJU Int; 2013 Aug; 112(4):E265-71. PubMed ID: 23432960 [TBL] [Abstract][Full Text] [Related]
78. Metabolic syndrome is associated with high grade Gleason score when prostate cancer is diagnosed on biopsy. De Nunzio C; Freedland SJ; Miano R; Trucchi A; Cantiani A; Carluccini A; Tubaro A Prostate; 2011 Oct; 71(14):1492-8. PubMed ID: 21360562 [TBL] [Abstract][Full Text] [Related]
79. Effect of Roux-en-Y gastric bypass on testosterone and prostate-specific antigen. Woodard G; Ahmed S; Podelski V; Hernandez-Boussard T; Presti J; Morton JM Br J Surg; 2012 May; 99(5):693-8. PubMed ID: 22302466 [TBL] [Abstract][Full Text] [Related]
80. The association of diabetes and positive prostate biopsy in a US veteran population. Moses KA; Utuama OA; Goodman M; Issa MM Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):70-4. PubMed ID: 21894176 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]